Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 4/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 3/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650339 | 0.92 | C5AR1 (0.41) | C5AR1MEN1KMT2ACRHR1TSHR | |
| SCHEMBL648764 | 0.91 | C5AR1 (0.40) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL648946 | 0.91 | C5AR1 (0.41) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL653237 | 0.90 | C5AR1 (0.40) | C5AR1MEN1KMT2ATRPV4ADORA2B | |
| SCHEMBL650285 | 0.90 | C5AR1 (0.41) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL650105 | 0.88 | C5AR1 (0.46) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL648525 | 0.88 | C5AR1 (0.40) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL649952 | 0.88 | C5AR1 (0.41) | C5AR1CRHR1TSHR | |
| SCHEMBL650152 | 0.88 | C5AR1 (0.40) | C5AR1MEN1KMT2ATRPV4CRHR1 | |
| SCHEMBL651014 | 0.87 | C5AR1 (0.41) | C5AR1CRHR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |